Outcomes of Intravenous Thrombolysis for Ischemic Stroke Therapy: Eighties Versus Younger Age Group
Abstract
Objective: Intravenous recombinant tissue plasminogen activator (rtPA) administered within 4.5 hours of symptom onset is the first available effective therapy for acute ischemic stroke. This study examined the characteristics, complications, and short-term outcome of ischemic stroke patients comparing between age groups, younger and older, treated with rtPA.
Methods: Retrospective study to analyze 211 patients with ischemic stroke treated with intravenous rtPA, aged > 80 years (n = 27) were compared with counterparts aged < 80 years (n = 184). Basic characteristics, risk factors, NIHSS score at admission and 90 days, symptom to needle time, blood pressure, size of infarction area, blood test results, MRS score at 90 days and death at hospital and 90 days after therapy were retrieved to determine outcome between age groups.
Results: All 211 patients, there were 27 patients (12.8%) in the older, and 184 patients (87.2%) in the younger. Baseline characteristics were no significant differences between age groups; sex, NIHSS score, size of infarction, blood pressure, risk factors, and laboratory results (p > 0.05). There were 3.7% in older and 20.65% in younger patients had intracerebral hemorrhage (ICH) (p = 0.034; OR = 0.15; 95% CI 0.02 to 1.12). Stroke mortality during admission in hospital and at 90 days was not significant difference between age groups. At 90 days follow up, NIHSS score and MRS score were no difference between age groups (p > 0.05). Outcome of this study showed no significant difference between age groups in baseline characteristics, NIHSS score and MRS score at 90 days follow up, ICH and mortality.
Conclusions: Older and younger patients had no difference in outcome; ICH, disability, and mortality after treatment with intravenous rtPA in the same baseline characteristics. Intravenous rtPA should be recommended treatment as standard therapy for all age groups.
References
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
3. Wardlaw JM. Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke. Where do we go from here? A cumulative meta-analysis. Stroke 2003;34:1437-42.
4. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-25.
5. แนวทางการรักษาโรคหลอดเลือดสมองตีบหรืออุดตัน สำหรับแพทย์. กรุงเทพฯ: สถาบันประสาทวิทยา; 2550.
6. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-80.
7. Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: from the Framingham Study. Stroke 1991;22:312-8.
8. Manolio TA, Kronmal RA, Burke GL, et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996;27:1479-86.
9. Asplund K, Carlberg B, Sundstrom G. Stroke in the elderly: observations in a population-based sample of hospitalized patients. Cerebrovasc Dis 1992;2:152-7.
10. Al Rajeh S. Stroke in the elderly aged 75 years and above. Cerebrovasc Dis 1994;4:402-6.
11. Sharma JC, Fletcher S, Vassallo M. Strokes in the elderly - higher acute and 3-month mortality - an explanation. Cerebrovasc Dis 1999;9(1):2-9.
12. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
13. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418-22.
14. Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995;45:649-58.
15. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998;129: 597-604.
16. Mouradian MS, Senthilselvan A, Jickling G, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry 2005;76:1234-7.
17. van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry 2006;77:375-7.
18. Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795-8.
19. Sylaja PN, Cote R, Buchan AM, et al. Thrombolysis for acute ischemic stroke patients aged 80 years and older: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826-9.
Downloads
Published
How to Cite
Issue
Section
License
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
